找回密碼
 To register

QQ登錄

只需一步，快速開(kāi)始

掃一掃，訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Adherence in Hypertension and Cardiovascular Protection; Michel Burnier Book 2018 Springer International Publishing AG, part of Sprin

[復(fù)制鏈接]
查看: 48228|回復(fù): 54
樓主
發(fā)表于 2025-3-21 19:25:01 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection
編輯Michel Burnier
視頻videohttp://file.papertrans.cn/284/283029/283029.mp4
概述Illustrates how to apply new technologies in assessing and monitoring drug adherence..Sheds light on the importance of adherence monitoring in clinical trials..Highlights the role of a multidisciplina
叢書(shū)名稱(chēng)Updates in Hypertension and Cardiovascular Protection
圖書(shū)封面Titlebook: Drug Adherence in Hypertension and Cardiovascular Protection; Michel Burnier Book 2018 Springer International Publishing AG, part of Sprin
描述.This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient‘s adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of sev
出版日期Book 2018
關(guān)鍵詞drug adherence monitoring; resistant hypertension; clinical trials; healthcare network; cost-effectivene
版次1
doihttps://doi.org/10.1007/978-3-319-76593-8
isbn_softcover978-3-030-09528-4
isbn_ebook978-3-319-76593-8Series ISSN 2366-4606 Series E-ISSN 2366-4614
issn_series 2366-4606
copyrightSpringer International Publishing AG, part of Springer Nature 2018
The information of publication is updating

書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection影響因子(影響力)




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection被引頻次




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection被引頻次學(xué)科排名




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection年度引用




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection年度引用學(xué)科排名




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection讀者反饋




書(shū)目名稱(chēng)Drug Adherence in Hypertension and Cardiovascular Protection讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:53:16 | 只看該作者
https://doi.org/10.1007/978-3-662-24745-7ons and a maximum of 2?hours of post-DOT-HTN observation. Three reports had longer observation time, two of them with medication administration intervals, and blood pressure measurement intervals. Two were case reports, describing severe post-DOT-HTN adverse reactions, contributing with important sa
板凳
發(fā)表于 2025-3-22 01:12:59 | 只看該作者
https://doi.org/10.1007/978-3-662-24745-7 cannot be assessed this way. These uncertainties reduce the value of biochemical monitoring. Biochemical monitoring of adherence should be preceded by informed consent unless it is performed for research purposes at the group level and with necessary ethical approval. The risk/benefit ratio of bioc
地板
發(fā)表于 2025-3-22 06:30:25 | 只看該作者
https://doi.org/10.1007/978-3-662-24745-7hers in lower tolerability. We discuss how this heterogeneity of treatment effect may lead to differential impacts of antihypertensive drugs on medication adherence among individual patients. We conclude by suggesting approaches to preventing adverse effects of antihypertensive drugs on medication a
5#
發(fā)表于 2025-3-22 10:46:37 | 只看該作者
6#
發(fā)表于 2025-3-22 15:32:48 | 只看該作者
https://doi.org/10.1007/978-3-662-24745-7e and avoid unnecessary treatment intensification. Given the expanding population with uncontrolled and resistant hypertension and emerging cost–benefits of adherence, addressing non-adherence to prescribed antihypertensive therapy is a top priority.
7#
發(fā)表于 2025-3-22 18:36:15 | 只看該作者
Adherence to Antihypertensive and Cardiovascular Preventive Treatment: The Contribution of the?Lombadherence to statin treatment; and (4) there was a significant positive relationship between reduced adherence to treatment and increased risk of hospitalization for coronary disease, cerebrovascular disease, and heart failure. This was the case in younger and older patients, including those >85 year
8#
發(fā)表于 2025-3-22 21:18:19 | 只看該作者
Directly Observed Therapy in Hypertension (DOT-HTN)ons and a maximum of 2?hours of post-DOT-HTN observation. Three reports had longer observation time, two of them with medication administration intervals, and blood pressure measurement intervals. Two were case reports, describing severe post-DOT-HTN adverse reactions, contributing with important sa
9#
發(fā)表于 2025-3-23 04:03:36 | 只看該作者
10#
發(fā)表于 2025-3-23 05:33:01 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 14:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
海林市| 长丰县| 乐平市| 拜城县| 德格县| 南乐县| 巴里| 克东县| 镶黄旗| 五峰| 隆尧县| 穆棱市| 长岛县| 西吉县| 启东市| 洛宁县| 河池市| 洱源县| 个旧市| 江门市| 蓬莱市| 商城县| 抚宁县| 黄陵县| 资兴市| 苏尼特右旗| 西盟| 新宁县| 衡水市| 湘潭县| 海盐县| 万盛区| 襄汾县| 屏东县| 芦溪县| 云安县| 大邑县| 渭南市| 手游| 阳城县| 沭阳县|